AU Patent

AU2024227694B2 — Methods of using a GIP/GLP1 co-agonist for therapy

Assigned to Eli Lilly and Co · Expires 2026-01-22 · 0y expired

What this patent protects

METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt 5 thereof. The present invention provides a method for impr…

USPTO Abstract

METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt 5 thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of 10 tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and/or treating dyslipidemia. METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY

Drugs covered by this patent

Patent Metadata

Patent number
AU2024227694B2
Jurisdiction
AU
Classification
—
Expires
2026-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.